Search form

Current Location

SistemBM™

Our methodologies can also be applied to define, qualify and validating miRNA biomarkers from biofluids and surgical samples for prediction, diagnostic, prognostic, monitoring, toxicity and end-point.

MiRNA’s are stable in both fresh-frozen and fixed, archive tissue compared to mRNA species. MiRNA signatures can be obtained from samples with a poor Ribosome Integrity Number (RIN). This, combined with the undisputed biological importance of miRNA’s, make the detection an attractive alternative to mRNA in samples where there are poor or variable RINs across the available sample cohort.

MiRNA’s in biofluids provide a non-invasive way to monitor these biomarkers and their translation from R&D to clinical translation. Species conservation may also be an important part of the process with many miRNA’s being conserved across a wide range of species including those routinely used in the pre-clinical setting including, mice, rats, pigs and horses.

Recent News

Glasgow, SCOTLAND. Sistemic Ltd. is excited to announce significant progress with the development of a miRNA-based assay for assessment of pluripotent stem cell (PSC) contamination in derived cell therapy products. The development is being undertaken in conjunction with LGC, the UK National Measurement Laboratory and Designated Institute for chemical and bio-measurement.

Sistemic Ltd. announced today the publication of its ground-breaking research, undertaken together with TiGenix, identifying a set of circulating miRNA biomarkers which could potentially be used, if further clinically validated, to stratify refractory rheumatoid arthritis patients, prior to treatment, into responders and non-responders to an allogenic cell-based therapy:

Our Products

Sistemic’s platform technology pioneering the approach and development of miRNA-based profiling tools to guide and support Cell Therapy (CT) product development and drug discovery and repositioning

Allows for robust miRNA profiling, customised multi-layered statistical analysis, and biological interpretation and identification of the key markers (KmiR’s™) of cell phenotype. Whilst also seeking to maximise the utility and value of the KmiR’s™ identified

Sistemic's methodologies can also be applied to define, qualify and validating miRNA biomarkers from biofluids and surgical samples for prediction, diagnostic, prognostic, monitoring, toxicity and end-point.

Sistemic’s highly curated knowledge from internal and external projects covering miRNA and cell therapy-based knowledge. The database includes kmiR™ lists from all analyses and high impact meta-data. The knowledgebase is fully integrated with SistemSeek™ literature database